Kaposi sarcoma (KS) is an endothelial malignancy caused by human herpes virus-8 (HHV-8) infection. The epidemic and iatrogenic forms of childhood KS result from a profound and acquired T cell deficiency. Recent studies have shown that classic KS of childhood can result from rare single-gene inborn errors of immunity, with mutations in WAS, IFNGR1, STIM1, and TNFRSF4. The pathogenesis of the endemic form of childhood KS has remained elusive. We review childhood KS pathogenesis and its relationship to inherited and acquired immunodeficiency to oncogenic HHV-8. Pediatrics Blood Cancer 2016;63:392–397. © 2015 The Authors. Pediatric Blood & Cancer, published by Wiley Periodicals, Inc.

Key words: Kaposi sarcoma; human herpes virus-8; HHV-8; pediatric; children

INTRODUCTION

Kaposi sarcoma (KS) is an inflammatory neoplasm of endothelial cell origin first defined by Hungarian dermatologist, Moritz Kaposi in 1872. [1] KS is probably a polyclonal proliferation of spindle cell latently infected by human herpes virus-8 (HHV-8), which often evolves into an oligoclonal monoclonal disorder. [2–4] It is currently classified under four epidemiologic forms: [5] Classic KS primarily affects elderly men mostly over 60 years old of Eastern European and Mediterranean origin, typically presenting with indolent and chronic cutaneous plaques and nodules. Endemic KS in Sub-Saharan Africa affects younger adults, with a rapidly progressive lymphadenopathic course. Epidemic KS in human immunodeficiency virus (HIV)-infected and acquired immune deficiency syndrome (AIDS) patients and iatrogenic KS in medically immunosuppressed (e.g., transplanted) patients typically follow a rapidly progressive course, affecting the skin, mucosae, lymphatic system, and visceral organs. HHV-8, also designated as KS-associated herpes virus (KSHV), is the causative agent for all epidemiological forms of KS in all patients. [6] The vast majority of HHV-8 infected individuals (more than 40% in some populations, based on seroprevalence) do not develop KS. [7] This virus can cause at least two other conditions, some forms of multicentric Castleman’s disease and primary effusion lymphoma, both of which can however occur in the absence of HHV-8 infection. [8]

The prevalence of HHV-8 varies globally, with high levels of more than 40% seropositivity in parts of Africa and South America, intermediate level of 30%–40% seropositivity in the Mediterranean, and low levels of up to 20% seropositivity in non-endemic areas such as North America, Northern Europe, and most of Asia. [7] There exists some major HHV-8 genotypes, many of which are geographically restricted, with little evidence to support whether any genotype is more virulent or more associated with KS. [9–13] In 2009, in addition to Hepatitis B Virus, Hepatitis C Virus, HIV-1, Human Papillomaviruses, and Human T-Cell Lymphotropic Virus Type-1, the World Health Organization’s International Agency for Research on Cancer declared HHV-8 a Group 1 carcinogenic virus, highlighting its public health significance. [14]
patients with systemic or organ-specific symptoms. Biopsy of the KS lesion is required for definitive diagnosis. Histologic features include spindle shaped cells, inflammatory infiltrates, and angioproliferation with erythrocyte extravasation. Endothelial cell markers (CD31, CD34, factor VIII) and lymphatic endothelial cell markers (lymphatic vessel endothelial receptor 1) are oftentimes useful to support the diagnosis of KS.[15] However, detection of HHV-8 latency-associated nuclear antigen, expressed in all clinical stages of KS, in spindle cells, which are the proliferating HHV-8-infected endothelial cells, is a more definitive histologic diagnosis.[15–17] AIDS-associated KS is staged according to the classification developed by the AIDS Clinical Trials Group Oncology Committee, which stratifies patients based on tumor burden, immune status, and presence of any systemic symptoms.[18] There is no validated staging system for the other epidemiologic forms of KS (classic, endemic, and iatrogenic).

For patients with epidemic or iatrogenic KS, the most effective treatment requires correcting the underlying immunodeficiency. The prognosis of epidemic KS has greatly improved with the use of highly active anti-retroviral therapies (HAART). However, KS remains the most common AIDS-associated malignancy worldwide and the common form of all cancers in adult males and the second or third most common cancer in women and children in many parts of Sub-Saharan Africa where HAART is not widely available,[19,20] posing a significant burden on human health worldwide. There is evidence that patients with iatrogenic KS, specifically those with renal transplants under cyclosporine immunosuppression, have had tumor regression when immunosuppression was switched to sirolimus, a mammalian target of rapamycin (mTOR) inhibitor sharing both immunosuppressive and anti-neoplastic effects.[21,22] Treatment for endemic and classic forms of KS is targeted on the basis of localized or disseminated disease. Symptomatic localized lesions are oftentimes treated with local measures such as intralesional vinblastine, liquid nitrogen, laser therapy, localized radiotherapy, topical retinoic acid, or surgical resection. For patients with multifocal, symptomatic, or disseminated disease requiring systemic therapy, liposomal doxorubicin or liposomal daunorubicin is the first line of choice followed by paclitaxel as second-line treatment.[23,24] Other modalities with activity against KS include vincristine, vinblastine, vinorelbine, bleomycin, and etoposide. Immunomodulation approaches, such as interferon-α (IFN-α), have been evaluated, with promising activity in limited disease in epidemic KS.[25]

KS in adults and HHV-8 infection in children have been the subjects of recent reviews.[8,26] There is however no review focused on pediatric KS. We will herein review childhood KS, our current understanding of all the epidemiologic forms, risk factors for KS development, as well as current treatment approaches. In particular, we will discuss childhood KS pathogenesis and its relationship to inherited and acquired immunodeficiency.

**CHILDHOOD KS**

**Epidemiology**

Epidemic and endemic KS. Pediatric KS (summarized in Table 1) is rare, but the prevalence greatly changes within regions of the world where HIV infection is widespread. Prior to the AIDS pandemic, the most frequent form of KS in children was the endemic KS in Africa. However, the insurgence of the AIDS pandemic has increased the incidence of pediatric KS by more than 40-fold, now making epidemic KS the most common form of pediatric KS worldwide.[27–29] In a study of 18 Sub-Saharan African countries, KS was the most common or second most common childhood cancer in many areas of Southern and Eastern Africa, with rates as high as 22% of all pediatric cancers in Uganda.[30] In a study conducted in Africa, HIV positive individuals have 47 times higher odds of KS development compared with the general population.[31] However, specific pediatric data are lacking. Furthermore, there is a paucity of literature on the epidemiology and pathogenesis of endemic (HHV negative) KS as a whole, in both the pre and post HIV pandemic era. In Sub-Saharan Africa, the proportion of endemic KS is estimated to be 36% (266 of the 726 KS cases in Zambia confirmed by pathologists who were HIV negative).[32] and that of pediatric endemic KS is estimated to be 11% (10 of the 92 children in Malawi).[20] The risk factors for endemic KS, and whether the incidence and prevalence is stable or increasing, are unknown.

Classic and iatrogenic KS. Pediatric classic and iatrogenic KS are extremely rare, despite the high seroprevalence of HHV-8 in certain regions of the world. In the Mediterranean Basin and certain African regions, seroprevalence can reach 50% in children older than 6 years.[33,34] and there is evidence for strong familial aggregation between mother–child and sibling–sibling relationships.[35,36] Classic KS in children is exceedingly rare, with less than 50 reported cases of classic KS in the last 50 years (Supplementary Table 1).[37–50] This corresponds to probably less than 1 case per million infected children. The epidemiology of HHV-8 infection and development of iatrogenic KS in the pediatric population has not yet been fully elucidated. However, data from adult patients with iatrogenic KS after solid organ transplantation indicates a cumulative risk range as low as 0.4% in North America to as high as 6% in regions of the Mediterranean and Middle East, a risk 1,000-fold greater than non-transplanted patients.[26,51]

Transmission of HHV-8. Horizontal transmission in infancy and childhood is thought to occur primarily through saliva exchange.[36,52] Although vertical transmission of HHV-8 has been reported, it is rare and estimated with an incidence of 2%. [53] Interestingly, breast milk transmission has not yet been reported despite the presence of HHV-8 DNA in breast milk of seropositive mothers.[54] Furthermore, there is evidence of HHV-8 transmission by blood transfusion in regions of the world where HHV-8 is endemic.[55]

**Clinical Course**

Epidemic KS in pediatric populations frequently follows a more aggressive course; sometimes without cutaneous involvement, and oftentimes involving mucosa and visceral organs. Children with epidemic KS are young (mean 8.8 years),[20] and KS immune reconstitution inflammatory syndrome (IRIS) can occur up to 20% of children with epidemic KS receiving HAART therapy.[56] Children with endemic KS tend to be younger (mean 6.6 years) and present with generalized or localized lymphadenopathy with sparse mucosal or skin lesions,
R1 deficiency, R1 deficiency is a well-defined X-linked recessive [XR] phenomenon. Doxorubicin, liposomal daunorubicin, paclitaxel, vincristine, and vinblastine are used for prevention of (primary) HHV-8 infection and subsequent KS development, with systemic chemotherapy (liposomal doxorubicin, liposomal daunorubicin, paclitaxel, vincristine, etoposide, and bleomycin) utilized in cases of pediatric KS with systemic disease, and intralesional chemotherapy (vinblastine, topical retinoic acid) utilized in cases of localized disease.[26] As in adults, the control of HIV and the switch or diminution of immunosuppression is key to the control of epidemic and iatrogenic forms. In cases of epidemic KS, the Cochrane review concluded that chemotherapy and HAART in combination versus HAART alone are more likely associated with KS remission, although data are sparse.[64,65] Children with endemic (African) KS who are HIV negative, oftentimes in resource-limited settings, have better outcomes than those with HIV infection undergoing the same chemotherapeutic regimens.[20,56,65–68] Limited cases of pediatric iatrogenic (liver transplant) KS have shown promising response to mTOR inhibitor sirolimus, and paclitaxel chemotherapy.[57,69] Pediatric classic (Mediterranean) KS, also exceedingly rare with very few case reports, has been treated with various modalities. Three Turkish children with disseminated classic KS had variable responses to systemic chemotherapy: one progressed and died on vincristine, another went into first remission after systemic IFN-α therapy, and a third child progressed despite systemic IFN-α and vinblastine but went into remission after etoposide.[45]

### Pathogenesis: Broad Acquired and Inborn Immunodeficiencies

HHV-8 seropositivity alone does not predict progression to childhood KS, and epidemic and iatrogenic KS attest of an immunodeficiency with greatly increased risk of KS. This suggests that endemic and classic childhood KS may also result from hitherto unknown forms of immunodeficiency, whether inherited or acquired. Human genetic variability may account for phenotypic variability in the clinical outcome of HHV-8 infection. Supporting the hypothesis that inborn errors may account for classic KS predisposition is the identification of children with known inherited immunodeficiencies (i.e., autosomal recessive [AR] IFN-γ R1 deficiency, X-linked recessive [XR] Wiskott–Aldrich syndrome) to have either preceding or concurrent KS (Table II).[44,46] IFN-γ R1 deficiency is a well-defined

**Table I. Four Types of Pediatric Kaposi Sarcoma**

| Type of KS     | Relative frequency | Geographic characteristic | Immunodeficiency                              | Clinical presentation                      |
|---------------|--------------------|---------------------------|-----------------------------------------------|-------------------------------------------|
| Epidemic      | Relatively common  | Worldwide                 | AIDS                                          | Aggressive; sometimes without cutaneous involvement, oftentimes involving mucosa and visceral organs, IRIS |
| Endemic       | Rare               | Sub-Saharan Africa        | Not yet deciphered                            | Generalized or localized lymphadenopathy with sparse mucosal or skin lesions, if any |
| Iatrogenic    | Very rare          | Developed world           | Immunosuppressive therapy, (e.g. transplantation) | Variable; lymphadenopathy, visceral, mucocutaneous or cutaneous involvement |
| Classic       | Exceedingly rare   | Mediterranean, European    | WAS, IFN-γ R1 deficiency, STIM1 deficiency, OX40 deficiency | Rapidly progressive disseminated and aggressive cutaneous lesions, oftentimes with mucosal and lymph node involvement |

**Abbreviations:** KS, Kaposi sarcoma; AIDS, acquired immunodeficiency syndrome; IRIS, immune reconstitution inflammatory syndrome; WAS, Wiskott–Aldrich syndrome.
primary immunodeficiency that predisposes to mycobacterial disease. There is report of a 10-year child from Turkish consanguineous parents, who had low intermittent but persistent CD4+ T cell counts and recurrent disseminated infection caused by Bacille Calmette-Guerin (BCG) vaccine and environmental Mycobacterium fortuitum since the age of 5 months. He concurrently developed aggressive disseminated cutaneous and systemic classic KS confirmed by skin biopsy, and died at 12 years of age of KS progression despite treatment with IFN-α and paclitaxel. Moreover, another report of a 14-month-old child with Wiskott–Aldrich syndrome from Tunisian non-consanguineous parents had a history of multiple bacterial (local infection caused by BCG vaccine, severe staphylococcal pneumonia) and viral infections (Epstein–Barr virus-related lymphoproliferative disease, cytomegalovirus viremia) including HHV-8 infection in aggressive disseminated cutaneous and systemic classic KS confirmed by skin biopsy. The cutaneous KS lesions partially regressed with paclitaxel but complete remission from KS was not obtained until non-T-cell depleted allogeneic hematopoietic stem cell transplant (HSCT). These two cases of classic KS in children with well-described primary immunodeficiency along with the observation of KS remission after HSCT, combined with the comprehension of epidemic and iatrogenic KS pathogenesis, lend further support to the critical role of a functioning immunity against HHV-8 infection and KS development.

Pathogenesis: Inborn Errors of Immunity to HHV-8

Indeed, the first two genetic etiologies of isolated KS (AR STIM1 deficiency and AR OX40 deficiency), both of which impair T cell immunity, were subsequently discovered (Table II). A 2-year female born to Turkish consanguineous parents with aggressive disseminated cutaneous and systemic KS died 4 months after presentation from pulmonary lesions. Although the counts and proportions of T, B, and NK cell subsets were normal, she harbored a homozygous splice-site mutation in STIM1, leading to primary functional T cell immunodeficiency. Subsequently, a 14-year-old female born to Turkish consanguineous parents, also with aggressive disseminated cutaneous and systemic classic KS confirmed by skin biopsy, was reported to carry a homozygous R65C null mutant allele in TNFRSF4 (encoding OX40). Ox40, normally expressed on activated T cells with its ligand (OX40L) expressed on endothelial cells, was lowly expressed on the patient’s activated T cell surface with abolition of binding to OX40L. She was treated with IFN-α, vinblastine, and etoposide with subsequent complete remission at last follow-up. These findings provided proof-of-principle that single-gene inborn errors of immunity can underlie aggressive forms of classic KS in childhood. Indeed, there are examples of single-gene inborn errors underlying early-onset cancers. Moreover, isolated childhood infectious diseases, including viral diseases such as herpes simplex encephalitis and severe influenza, can be caused by single-gene immunodeficiencies. Epidermodysplasia verruciformis, an AR predisposition to papillomavirus-driven non-melanoma skin cancer caused by mutations in EVER1 or EVER2, neatly illustrates both the aspects. Altogether, the observation of (1) HIV infection with low CD4+ T cell predisposition to epidemic KS, (2) T cell immunosuppression in iatrogenic KS, and (3) T cell impairment in children with classic KS (AR IFN-γR1 deficiency, XR Wiskott–Aldrich syndrome, AR STIM1 deficiency, and AR OX40 deficiency) suggest that HHV-8 exposure alone is insufficient and impaired T cell responses underlie the development of KS. Although progress has been made in our understanding of KS-predisposing inborn errors of immunity with the identification of two inborn errors of T cell immunity in two unrelated kindreds, the genetic etiology of classic KS in children remains largely unexplained. Moreover, the pathogenesis of endemic childhood KS remains unknown. Next-generation sequencing, with exome and genome sequencing, offers a promising avenue of research in both familial and sporadic cases.

### Table II. Genetic Predisposition to Pediatric Kaposi Sarcoma

| Gene      | Type | Inheritance | PID                  | Onset age | Presentation                                      | Clinical outcome         |
|-----------|------|-------------|----------------------|-----------|--------------------------------------------------|--------------------------|
| WAS       | Classic | XR         | Wiskott–Aldrich syndrome | 14 months | Aggressive disseminated cutaneous and systemic KS | Complete remission       |
| IFNGRI    | Classic | AR         | IFN-γR1 deficiency   | 10 years  | Aggressive disseminated cutaneous and systemic KS | KS progression and death |
| STIM1     | Classic | AR         | STIM1 deficiency     | 2 years   | Aggressive disseminated cutaneous and systemic KS | KS progression and death |
| TNFRSF4   | Classic | AR         | OX40 deficiency      | 14 years  | Aggressive disseminated cutaneous and systemic KS | Complete remission       |

**Abbreviations:** KS, Kaposi sarcoma; XR, X-linked recessive; AR, autosomal recessive; PID, pediatric immunodeficiency.
inborn errors of immunity may underlie the pathogenesis of the classic and perhaps even endemic forms of this malignancy in childhood. We aim to bring attention of the pediatric community to large to childhood KS, highlighting that human genetic studies of both classic (Mediterranean) and endemic (African) KS of childhood may provide new directions in understanding the pathogenesis of all epidemiological forms of KS, in children and adults. This may not only be helpful to patients with KS and other HHV-8-related diseases, for diagnosis, prognosis, and therapeutic benefits, but also to patients with other virus-driven cancers.

ACKNOWLEDGMENTS

We thank all members of the laboratory for helpful discussions. Carolyn C. Jackson is a Damon Runyon Physician-Scientist supported (in part) by the Damon Runyon Cancer Research Foundation (PST-03-15).

REFERENCES

1. Kapoor M. Idiopathic multiple pigmented sarcomas of the adult. Arch Dermatol Syphilol 1872;4:263-273.
2. Addo TG, Lacoste V, Briese J, Kasse-Kehlben E, Clye Y, Couppie P, Buchvizer C, Tuxlce M, Morvan J, Gessain A. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequence in Kaposi's sequences and other diseases. J Natl Cancer Inst 2009;101:729-736.
3. Duprez R, Lacoste V, Briese J, Couppie P, Frances C, Sainte-Marie D, Kasase-Keehlen E, Lando MJ, Assane Oyunje Y, Nkogbou B, Hibo O, Mahe A, Lebe C, Tortevoye P, Huere M, Gessain A. Evidence for a monoclonal origin of multicentric advanced lesions of Kaposi's sarcoma. J Natl Cancer Inst 2007;99:1069-1074.
4. Russo JJ, Bohlen RA, Chen MC, Chen J, Yan M, Maddakala D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS. Nucleotide sequence of Kaposi's sarcoma-associated herpesvirus (KSHV) type A. J Virol 2001;75:3155-3164.
5. Antin M, Chang Y, Kaposi's sarcoma. N Engl J Med 2002;346:1027-1038.
6. Chang Y, Creasman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PR. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-1869.
7. Mesi EA, Creasman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010;10:707-719.
8. Bhutani M, Polizotto MN, Udlicki TS, Yarchoan R. Kaposi sarcoma-associated herpesvirus-associated malignancies: Epidemiology, pathogenesis, and advances in treatment. Semin Oncol 2015;42:235-246.
9. Dittmer DP, Damania B. Kaposi sarcoma-associated herpesvirus pathogenesis (KSHV)-an update. Curr Opin Virol 2013;3:238-244.
10. Hosenipour MC, Sweet KM, Xiong J, Namakula J, Mwinefo A, Nyirenda M, Chiwoko L, Matsen M, Donze J, Mouquet J, Nkogbou B, Hibo O, Mahe A, Lebe C, Tortevoye P, Huere M, Gessain A. Evidence for monoclonal origin of multicentric advanced lesions of Kaposi's sarcoma. J Natl Cancer Inst 2007;99:1069-1074.
11. Russo JJ, Bohlen RA, Chen MC, Chen J, Yan M, Maddakala D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS. Nucleotide sequence of the Kaposi's sarcoma-associated herpesvirus (KSHV) type A. J Virol 2001;75:3155-3164.
12. Chang Y, Creasman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PR. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-1869.
13. Zhang YJ, Davis JL, Chang Y, Moore PR. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (KSHV) type A. J Virol 2001;75:3155-3164.
14. Mesi EA, Creasman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010;10:707-719.
15. Bhutani M, Polizotto MN, Udlicki TS, Yarchoan R. Kaposi sarcoma-associated herpesvirus-associated malignancies: Epidemiology, pathogenesis, and advances in treatment. Semin Oncol 2015;42:235-246.
16. Dittmer DP, Damania B. Kaposi sarcoma-associated herpesvirus pathogenesis (KSHV)-an update. Curr Opin Virol 2013;3:238-244.
17. Hosenipour MC, Sweet KM, Xiong J, Namakula J, Mwinefo A, Nyirenda M, Chiwoko L, Matsen M, Donze J, Mouquet J, Nkogbou B, Hibo O, Mahe A, Lebe C, Tortevoye P, Huere M, Gessain A. Evidence for monoclonal origin of multicentric advanced lesions of Kaposi's sarcoma. J Natl Cancer Inst 2007;99:1069-1074.
18. Russo JJ, Bohlen RA, Chen MC, Chen J, Yan M, Maddakala D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS. Nucleotide sequence of the Kaposi's sarcoma-associated herpesvirus (KSHV) type A. J Virol 2001;75:3155-3164.
19. Zhang YJ, Davis JL, Chang Y, Moore PR. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (KSHV) type A. J Virol 2001;75:3155-3164.
59. Malla I, Perez C, Cheang Y, Silva M. Human herpesvirus 8 related Kaposis’s sarcoma in a pediatric liver transplant recipient: Case report. Arch Argent Pediatr 2013;111:450–453.

60. Salas I, Faraiz M, Magnano GM, Sementa A, di Marco E, Garaventa A, Micalizzi C, Lannino E, Morreale G, Moroni C, Castagnola E. HIV-8-related visceral Kaposis sarcoma following allogeneic HSCT: Report of a pediatric case and literature review. Pediatr Transplant 2011;15: E8–11.

61. Varela-Fascinetto G, Hernandez-Plata JA, Nieto-Zermeño J, Alcantar-Fierros JM, Fuentes-Garcia V, Castaneda-Martinez P, Valencia-Mayoral P, Salgado-Ramírez JM. Pediatric liver transplant program at Hospital Infantil de Mexico Federico Gomez. Rev Invest Clin 2011;63 (Suppl 1): 57–61.

62. Andreoni M, Sarmati L, Nicastri E, El Sawaf G, El Zalabani M, Uccella I, Bugarini R, Parisi SG, Rezza G. Primary human herpesvirus 8 infection in immunocompetent children. JAMA 2002;287:1295–1300.

63. Luppi M, Barozzi P, Schiavo TF, Setti G, Staaks K, Trovato R, Nami F, Donelli A, Maiorana A, Marasca R, Sandrini S, Torelli G. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 2000;343:1378–1385.

64. Anglemyer A, Agrawal AK, Rutherford GW. Treatment of Kaposis sarcoma in children with HIV-1 infection. Cochrane Database Syst Rev 2010;1:CD009826.

65. Vaz P, Macassa E, Jami I, Thome B, Mahagaja E, Mwando T, Muando V, Biberfeld G, Anderson S, Blanche S. Treatment of Kaposis sarcoma in human immunodeficiency virus-infected Mozambican children with antiretroviral drugs and chemotherapy. Pediatr Infect Dis J 2011;30:891–893.

66. Gianfito A, Kakuwa A, Wild A, Wulansana V, Corey L, Casper C, Orem J. Clinical presentation and outcome of epidemic Kaposis sarcoma in Ugandan children. Pediatr Blood Cancer 2010;54:670–674.

67. Moloney E, Davidson A, Orem J, Hanrahan P, Bulagaddo-Kambugu J, Gitahangi J, Israel S. The management of children with Kaposis sarcoma in resource limited settings. Pediatr Blood Cancer 2013;60:538–542.

68. Stefan DC, Stones DK, Wainwright L, Newton R. Kaposis sarcoma in South African children. Pediatr Blood Cancer 2011;56:392–396.

69. Yuksekay HA, Arikian C, Yazici A, Baran M, Aydogdu S, Kılıç M. Successful treatment of a child having generalized Kaposis’s sarcoma after living donor liver transplantation with conversion to sirolimus. Pediatr Transplant 2009;13:375–378.

70. Byun M, Abhyankar A, Lelarge V, Plancoet S, Palanduz A, Elzanat L, Boisson B, Picard C, Dewell S, Zhao C, Jouanguy E, Feske S, Abel L, Casanova JL. Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposis sarcoma. J Exp Med 2010;207:2307–2312.

71. Byun M, Ma CS, Akay A, Pedreganna V, Paludritra U, Myoung J, Arvey DT, Liu Y, Abhyankar A, Lorenzo L, Schmidt M, Lim HK, Casar O, Miquel M, Rozenberg F, Campoli L, Noyan G, Fleckenstein B, Butzamante J, Picard C, Gessain A, Jouanguy E, Casar O, Obi M, Grof P, Abel L, Croft M, Tangye SG, Casanova JL. Inherited human OX40 deficiency underlying classic Kaposis sarcoma of childhood. J Exp Med 2013;210:1743–1759.

72. D’Orazio JA, Inherited cancer syndromes in children and young adults. J Pediatr Hematol Oncol 2010;32:195–228.

73. Casanova JL, Abel L. The genetic theory of infectious diseases: A brief history and selected illustrations. Ann Rev Genomics Hum Genet 2013;14:215–243.

74. Ciancanelli MJ, Huang SX, Luthra P, Garner H, Itan Y, Volps S, Lafaille FG, Trouillet C, Schmolke M, Albrecht RA, Israelsson E, Lim HK, Casado M, Hermet T, Lorenzo L, Leung LW, Pedreganna V, Boisson B, Okada S, Picard C, Rinquer B, Troussier F, Chausseb D, Abel L, Pfeifer I, Notarangelo LD, Garcia-Sastre A, Basler CF, Geissmann F, Zhang SY, Snoeck HW, Casanova JL. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science 2015.

75. Crequer A, Picard C, Pedreganna V, Lim A, Zhang SY, Abel L, Majewski S, Casanova JL, Jablonka S, Orlo G, Jouanguy E. EVER2 deficiency is associated with mild T-cell abnormalities. J Clin Immunol 2013;33:14–21.

76. Crequer A, Troeger A, Patin E, Ma CS, Picard C, Pedreganna V, Fischl C, Lim A, Abhyankar A, Gineau L, Muller-Fleckenstein I, Schmidt M, Taeb A, Krueger J, Abel L, Tange SG, Orlo G, Williams D, Casanova JL, Jouanguy E. Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest 2012;122:3239–3247.

77. Orth G. Host defenses against human papillomaviruses: Lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol 2008;321:59–83.

78. Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: Lessons from primary immunodeficiencies. J Exp Med 2014;211:2107–2119.

79. Snyder MW, Adey A, Shendure J. Haplotype-resolved genome sequencing: Experimental methods and applications. Nat Genet 2015;16:344–358.